The award, funded by the U.S. Army, was accepted on behalf of Geneva-funded researcher V. Sujith Sajja, PhD BETHESDA, Md. – The Geneva Foundation (Geneva), a 501(c)3 non-profit that provides innovative scientific research and exceptional program management, announces today the award of a $2.1 million dollar cooperative agreement from the U.S. Army Medical Research Acquisition
TACOMA, Wash. – The Geneva Foundation (Geneva), a 501(c)3 non-profit that provides innovative scientific research and exceptional program management, announces today the award of GSA Schedule (Contract No. 47QRAA21D009K) under the Multiple Award Schedule (MAS) from the General Services Administration (GSA) to further advance military medical research. Geneva’s government-wide MAS contract has an award period
Geneva is proud to be a founding member of the consortium which brings together a wealth of resources in North Carolina to provide world-class solutions for the military. Published by: RTI International Publish Date: 25 August 2021 RESEARCH TRIANGLE PARK, N.C. — A newly launched consortium led by RTI International and comprised of
Geneva has been selected to support a monoclonal antibody protocol under this public-private partnership at two military treatment facilities. TACOMA, WA – The Geneva Foundation (Geneva) announces today it has entered into a Cooperative Research and Development Agreement (CRADA) to conduct clinical trials at two military treatment facilities under the Accelerating COVID-19 Therapeutic Interventions
The Geneva Foundation (Geneva) is partnering with National Cancer Institute (NCI) scientists and the U.S. Army on two investigational grants for breast cancer research using novel antibody-drug conjugates. Geneva Principal Investigator Martin J. Schenermann, PhD, a senior investigator at the National Cancer Institute (NCI) and Principal Investigator Brad St. Croix, PhD, a senior scientist also at
The USU-4DBio3 Center for Biotechnology, administered by Geneva, ensures warfighters are supported with cutting-edge technologies. BETHESDA, MD – The Geneva Foundation (Geneva) announces today the official designation of the Biotechnology, Biomanufacturing, and Bioprinting Program (4DBio3) as a Uniformed Services University (USU) Center. The USU-4DBio3 Center for Biotechnology, derived from the 4DBio3 Program and administered by The
COL (Ret.) Kent Kester, MD is appointed as the SAB’s Board Chair. The Geneva Foundation (Geneva) announces today the appointment of four new members to its Scientific Advisory Board (SAB) which provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. “It is a great honor to
Previous Geneva Vice Chair Neil Vining, MD, MBA is appointed Board Chair. The Geneva Foundation (Geneva) announces changes to its Board of Directors with several new additions and the appointment of Dr. Neil Vining as Chair. The additions, and appointment of a new Chair, come as several long-serving members retired from the Board of Directors in
Lt. Col. (P) Eckert and Capt. Lammers will present their research findings to the public next month at the 34th East Annual Scientific Assembly. During acute trauma scenarios, medical personnel are in a battle with time as the challenge becomes: is there enough time to stop ongoing blood loss? Hemorrhage from major trauma is
Renowned lung injury Research Scientist Andriy Batchinsky, MD has been named The Geneva Foundation’s (Geneva) 2019 Researcher of the Year in recognition of his long-standing career pursuing ground-breaking treatments for the management of acute respiratory distress syndrome (ARDS), with notable contributions in research quality and research mentorship. Andriy Batchinsky, MD Dr. Batchinsky is a principal investigator